



Sheet 1 of 5

Form PTO-1449 <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b> (Use several sheets if necessary)		ATTY DOCKET NO. 06076	APPLICATION NO. 10/582,778			
		APPLICANT Jean Lafay et al				
		FILING DATE August 17, 2006	GROUP 1626			
<b>U.S. PATENT DOCUMENTS</b>						
EXAMINE R INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
<b>FOREIGN PATENT DOCUMENTS</b>				TRANSLATION		
DOCUMENT NUMBER	DATE	COUNTRY	CLASS			
<b>OTHER DOCUMENTS</b> (Including Author, Title, Date, Pertinent Pages, etc.)						
	Supuran et al "Carbonic Anhydrase, It's Inhibitors and Activators", CRC, 2004, title page and table of contents).					
	Yue et al "Determinants of Tissue Estradiol Levels and Biologic Responsiveness in Breast Tumors" Breast Cancer Research & Treatment 1998 pp 51-57.					
	Smith et al "Fadrozole and Letrozole ...Breast Cancer: Clinical and Biochemical effects" Breast Cancer Research & Treatment 1998 pp S67-S71.					
	Singh et al "Biochemical Control of Breast Aromatase" Breast Cancer Research & Treatment 1998 pp S9-S14.					
	Shenton et al "Comparison of Biochemical Aromatase Activity ...Imunhistochemistry in Human Breast Carcinomas" Breast Cancer Research & Treatment 1998 pp S101-S107.					
	Sasano et al "Immunolocalization of Aromatase in Human Breast Disorders Using Different Antibodies" Breast Cancer Research & Treatment 1998 pp S79-S84.					
	Santen et al "Demonstration of Aromatase Activity and Its Regulation in Breast Tumor and Benign Breast Fibroblasts" Breast Cancer Research & Treatment 1998 pp S93-S99.					
	Miller et al "Clinical Importance of Intratumoral Aromatase" Breast Cancer Research & Treatment 1998 S27-S32.					
	Brodie et al "Intratumoral Aromatase Model: The Effects of Letrozole (CGS 20267)" Breast Cancer Research & Treatment 1998 pp. S23-S26.					
EXAMINER	DATE CONSIDERED					
<small>EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>						

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.H./

Form PTO-1449

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

(Use several sheets if necessary)

ATTY DOCKET NO.  
06076APPLICATION NO.  
10/582,778APPLICANT  
Jean Lafay et alFILING DATE  
August 17, 2006GROUP  
1626

## U.S. PATENT DOCUMENTS

EXAMINE R INITIAL	DOCUMENT NUMBER				DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
						YES	NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

	Lonning et al, "Pharmacological and Clinical Profile of Anastrozole", Breast Cancer Research & Treatment 1998 pp S53-S57.
	Lonning et al, "Pharmacological Profiles of Exemestane and Formestane, Steroidal Aromatase Inhibitors Used for Treatment of Postmenopausal Breast Cancer" Breast Cancer Research & Treatment 1998 pp S45-S52.
	Harada et al "Molecular Analysis of Aberrant Expression of Aromatase in Breast Cancer Tissues" Breast Cancer Research & Treatment 1998 pp S15-S21.
	Goss "Pre-Clinical and Clinical Review of Vorozole, ...Generation Aromatase Inhibitor" Breast Cancer Research & Treatment 1998 pp S59-S65.
	Dowsett "Theoretical Considerations for the Ideal Aromatase Inhibitor" Breast Cancer Research & Treatment 1998 pp S39-S44.
	"Discussion of Session 1" Breast Cancer Research & Treatment 1998 pp S33-S37.
	"Discussion of Session 2" Breast Cancer Research & Treatment 1998 pp S73-S77.
	"Discussion of Session 3" Breast Cancer Research & Treatment 1998 pp S109-S119.
	Brodie "Aromatase Expression in the Human Breast" Breast Cancer Research & Treatment 1998 pp S85-S91.
	Singh et al "The Regulation of Aromatase Activity in Breast Fibroblasts: The Role of Interleukin-6 and Prostaglandin E <sub>2</sub> " Endocrine-Related Cancer 1999 pp 139,147.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.H./

Form PTO-1449				ATTY DOCKET NO. 06076		APPLICATION NO. 10/582,778		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION				APPLICANT Jean Lafay et al				
(Use several sheets if necessary)				FILING DATE August 17, 2006		GROUP 1626		
<b>U.S. PATENT DOCUMENTS</b>								
EXAMINE R INITIAL	DOCUMENT NUMBER			DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
<b>FOREIGN PATENT DOCUMENTS</b>								
	DOCUMENT NUMBER			DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES      NO
<b>OTHER DOCUMENTS</b> (Including Author, Title, Date, Pertinent Pages, etc.)								
	Simpson et al "Local Estrogen Biosynthesis in Males and Females" 1999 Endocrine-Related Cancer, pp 131-137.							
	Sasano et al "Effects of Aromatase Inhibitors on the Pathobiology of Human Breast, Endometrial and Ovarian Carcinoma" 1999 Endocrine-Related Cancer pp 197-204.							
	Santen et al "The Potential of Aromatase Inhibitors in Breast Cancer Prevention" 1999 Endocrine-Related Cancer pp 235-243.							
	Santen et al "Use of Aromatase Inhibitors in Breast Carcinoma" 1999 Endocrine-Related Cancer pp 75-92.							
	Ragaz "Status of Aromatase Inhibitors in Relation to Other Breast Cancer Treatment Modalities" 1999 Endocrine-Related Cancer pp 277-291.							
	Probst-Hensch et al "Aromatase and Breast Cancer Susceptibility" 1999 Endocrine-Related Cancer pp 165-173.							
	Osborne "Aromatase Inhibitors in Relation to Other Forms of Endocrine Therapy for Breast Cancer" 1999 Endocrine-Related Cancer pp 271-276.							
	Miller "Biology of Aromatase Inhibitors: Pharmacology/Endocrinology Within the Breast" 1999 Endocrine-Related Cancer pp 187-195.							
	Manni "Hormonal Approaches to the Chemo-Prevention of Endocrine-Dependent Tumors" 1999 Endocrine-Related Cancer pp 483-485.							
EXAMINER				DATE CONSIDERED				
EXAMINER: Initial if citation considered, whether or not citation is in conformance with H.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.H./

Form PTO-1449				ATTY DOCKET NO. 06076	APPLICATION No. 10/582,778		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION				APPLICANT Jean Lafay et al			
(Use several sheets if necessary)				FILING DATE August 17, 2006	GROUP 1626		
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINE R INITIAL	DOCUMENT NUMBER			DATE	NAME	CLASS SUB CLASS	FILING DATE IF APPROPRIATE
<b>FOREIGN PATENT DOCUMENTS</b>							
	DOCUMENT NUMBER			DATE	COUNTRY	CLASS SUB CLASS	TRANSLATION YES NO
<b>OTHER DOCUMENTS</b> (Including Author, Title, Date, Pertinent Pages, etc.)							
		Ingle et al "Combination Hormonal Therapy Involving Aromatase Inhibitors in the Management of Women with Breast Cancer" 1999 Endocrine-Related Cancer pp 265-269.					
		Lonning "Cross-resistance to different Aromatase Inhibitors in Breast Cancer Treatment" 1999 Endocrine-Related Cancer pp 251-257.					
		Harada et al "Aromatase Inhibitors and Enzyme Stability" 1999 Endocrine-Related Cancer pp 211-218.					
		Goss "Risks Versus Benefits in the Clinical Application of Aromatase Inhibitors" 1999 Endocrine-Related Cancer pp 325-332.					
		Feuillan et al "Use of Aromatase Inhibitors in Precocious Puberty" 1999 Endocrine-Related Cancer pp 303-306.					
		Dowsett "Drug and Hormone Interactions of Aromatase Inhibitors" 1999 Endocrine-Related Cancer pp 181-185.					
		Dixon et al "Lessons From the Use of Aromatase Inhibitors in the Neoadjuvant Setting" 1999 Endocrine-Related Cancer pp 227-230.					
		Coombes et al "Aromatase Inhibitors and Their Use in the Sequential Setting" 1999 Endocrine-Related Cancer pp 259-263.					
		Chen et al "Breast tumor Aromatase:Functional Role and Transcriptional Regulation" 1999 Endocrine-Related Cancer pp 149-156.					
EXAMINER			DATE CONSIDERED				
<small>EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>							

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.H./

Form PTO-1449				ATTY DOCKET NO. 06076	APPLICATION No. 10/582,778		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION				APPLICANT Jean Lafay et al			
(Use several sheets if necessary)				FILING DATE August 17, 2006	GROUP 1626		
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINE R INITIAL	DOCUMENT NUMBER		DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
<b>FOREIGN PATENT DOCUMENTS</b>							
	DOCUMENT NUMBER		DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION
							YES
							NO
<b>OTHER DOCUMENTS</b> (Including Author, Title, Date, Pertinent Pages, etc.)							
	Buzdar "Role of Aromatase Inhibitors in Advanced Breast Cancer" 1999 Endocrine-Related Cancer pp 219-225.						
	Bulun et al "Estrogen Production in Endometriosis and Use of Aromatase Inhibitors to Treat Endometriosis" Endocrine-Related Cancer pp 293-301.						
	Brodie et al "Aromatase and its Inhibitors:New Biology and Clinical Perspectives" 1999 Endocrine-Related Cancer pp 127-130.						
	Brodie et al "Aromatase Inhibitors and their Antitumor Effects in Model Systems" 1999 Endocrine-Related Cancer pp 205-210.						
	Braunstein "Aromatase and Gynecomastia" 1999 Endocrine-Related Cancer pp 315-324.						
	Baum "Use of Aromatase Inhibitors in the Adjuvant Treatment of Breast Cancer" 1999 Endocrine-Related Cancer pp 231-234.						
	Smith "Aromatase Inhibitors:a Dose-Response Effect?" 1999 Endocrine-Related Cancer pp 245-246.						
	Tekmal et al "Aromatase Overexpression and Breast Hyperplasia,...and Aromatase Inhibitors Abrogate these Preneoplastic Changes in Mammary Glands" 1999 Endocrine-Related Cancer pp 307-314.						
	Yue et al "Aromatase Within the Breast" 1999 Endocrine-Related Cancer pp 157-164.						
EXAMINER	/Robert Havlin/ (05/20/2010)		DATE CONSIDERED		05/20/2010		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.H./